Acadia Pharmaceuticals
ACAD
227 hedge funds and large institutions have $2.48B invested in Acadia Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 73 increasing their positions, 80 reducing their positions, and 23 closing their positions.
183% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $4M
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
1.85% more ownership
Funds ownership: 94.17% → 96.01% (+1.8%)
2% more funds holding
Funds holding: 223 → 227 (+4)
1% less capital invested
Capital invested by funds: $2.49B → $2.48B (-$18M)
9% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 80
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.4M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$15.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15M |
| 4 |
Man Group
London,
United Kingdom
|
+$14.6M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$20.7M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$12.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.57M |
| 5 |
Squarepoint
New York
|
-$7.79M |
ACAD Hedge Fund Activity: Q4 2022 in Review
227 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2022, worth a combined $2.48B — down 0.72% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ACAD positions and 23 closed out — a net gain of 7 holders — while 73 added to existing stakes and 80 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $17.4M. The largest seller was Fidelity Investments, cutting an estimated $35M.
- 227 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2022, up from 223 in Q3 2022.
- Funds reported $2.48B of Acadia Pharmaceuticals stock for Q4 2022, down 0.72% quarter-over-quarter.
- 30 funds opened new Acadia Pharmaceuticals positions in Q4 2022 and 23 closed out, a net change of +7 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2022 was Point72 Asset Management, an estimated $17.4M added.
- The largest Acadia Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $35M sold.
Based on aggregated 13F filings for Q4 2022.